Keystone Resort Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2001



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

AIDS Vaccines in the New Millennium (J8)


Organizer(s) R. Paul Johnson, Mark B. Feinberg and Emilio A. Emini
March 28—April 3, 2001
Keystone Resort • Keystone, Colorado USA
Abstract Deadline: Nov 28, 2000
Late Abstract Deadline:
Scholarship Deadline:
Early Registration Deadline: Jan 29, 2001

Sponsored by Wyeth-Lederle Vaccines

Joint Meeting: HIV Pathogenesis (J7)

Summary of Meeting:
The last few years have witnessed remarkable progress in scientific studies relevant to the development of an AIDS vaccine. Emerging data from both human and animal studies are providing novel insights into the immunological mechanisms that contain HIV infection. A variety of new vaccine approaches show promise in inducing a broad range of immune responses, and are now being tested in animal models and human clinical trials. Several recent technical advances have provided critical information on the structure of the envelope glycoprotein and new tools for the quantitative analysis of immune responses. Yet, many fundamental and practical challenges remain, and it is unclear whether any of the existing approaches will result in a safe and effective AIDS vaccine. This Keystone Symposium is intended to foster communication of the most current results, from basic and applied HIV vaccine research efforts, to integrate this information in the context of recent advances on AIDS pathogenesis, to identify and address obstacles to vaccine development, and to stimulate accelerated research on HIV vaccines.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


WEDNESDAY, MARCH 28

14:00—19:00
Registration

Shavano Foyer
18:15—19:15
Welcome

Shavano Foyer/Lobby
19:15—19:30
Orientation

Crestone/Red Cloud
19:30—21:30
Keynote Address (Joint)
Meeting has ended...abstracts no longer viewable online.

Crestone/Red Cloud
Gary J. Nabel, Sanofi, USA
AIDS Vaccines: Challenges and Opportunities

Ashley T. Haase, University of Minnesota, USA
Life in the Fast Lane in a Slow Infection: Implications for Vaccine Development of Events in Early Infection


THURSDAY, MARCH 29

07:00—08:00
Breakfast

Torreys/Castle Peaks
08:00—11:00
Cellular Immune Responses and Protective Immunity (Joint)
Meeting has ended...abstracts no longer viewable online.

Crestone/Red Cloud
Andrew J. McMichael, Oxford University, UK
Role of CTL in Control and Prevention of HIV Infection

* Bruce D. Walker, Ragon Institute of MGH, MIT and Harvard, USA
Immune Control of HIV Infection

Dan H. Barouch, Beth Israel Deaconess Medical Center, USA
Vaccine-Elicited Control of Viremia and Prevention of Clinical AIDS in Rhesus Monkeys

Robert Paul Johnson, Harvard Medical School, New England Primate Research Center, USA
Protective Immunity Induced by Attenuated Simian Immunodeficiency Virus

09:20—09:40
Coffee Break

Shavano Foyer/Lobby
11:00—13:00
Poster Setup

Torreys/Shavano
14:00—16:00
VACCINES WORKSHOP 1: Biological Considerations in the Evaluation of Candidate AIDS Vaccines

Crestone
* Sarah L. Rowland-Jones, Oxford University, UK
HIV Specific CTL in Genetically Diverse Populations

Bette Tina Marie Korber, Los Alamos National Laboratory, USA
The Implications of Global Variation of HIV for Vaccine Design

Philip J. Goulder, University of Oxford, UK
Analysis of HIV-1 Specific CTL Responses in South Africa Adults and Children

Mary Carrington, NCI, National Institutes of Health, USA
HLA Diversity and AIDS Vaccine Trials


Following Session is for HIV Pathogenesis (J7)

14:00—16:00
WORKSHOP 1: Soluble Modulators of HIV Infection

Red Cloud
* Jay A. Levy, University of California, San Francisco, USA
CD8+ Cell Noncytotoxic Anti-HIV Response Can Prevent Virus Infection and Pathogenesis

Paolo Lusso, San Raffaele Scientific Institute, Italy
Chemokines and Derivatives as Potential Anti-HIV Agents

Reinhard Kurth, Ernst Schering Foundation, Germany
HIV-Pathogenesis: What Protects the SIV-Infected Natural Host Primate from Development of AIDS?

J. Norman Flynn, University of Glasgow, UK
Involvement of Cytolytic and Non-Cytolytic T Cells in the Control of Feline Immunodeficiency Virus

Tae-Wook Chun, NIAID, National Institutes of Health, USA
Suppression of HIV Replication in the Resting CD4+ T Cell Reservoir by Autologous CD8+ T Cells: Implications for the Development of the Therapeutic Strategies

Karen F.T. Copeland, Ottawa Hospital Research Institute, Canada
Role of CD8+ T Cell Infection on Cellular Function

Mary E. Klotman, Mount Sinai School of Medicine, USA
Purification and Characterization of Soluble HIV Suppressive Factors from CD8+ Cells

David J. Volsky, Columbia University, St. Luke's Roosevelt Hospital Center, USA
Induction of Secretable Anti-HIV Factor in CD4-Positive T Cells

16:00—18:00
POSTER SESSION 1: Cellular Immune Responses and Protective Immunity/Envelope Glycoprotein: Structure, Function and Immune Responses

Torreys/Shavano
17:00—18:00
Social Hour

Shavano Foyer/Lobby
20:00—21:00
Coffee Available

Shavano Foyer/Lobby
20:00—22:00
Envelope Glycoprotein: Structure, Function and Immune Responses (Joint)
Meeting has ended...abstracts no longer viewable online.

Crestone/Red Cloud
William C. Olson, Regeneron Pharmaceuticals, Inc., USA
Studies on Disulfide-Stabilized HIV Envelope Glycoproteins

* James A. Hoxie, University of Pennsylvania, USA
Lessons Learned from CD4 Independent Isolates of HIV and SIV

Peter S. Kim, Stanford University, USA
Inhibiting HIV Entry

Erica Ollmann Saphire, The Scripps Research Institute, USA
Short Talk: The Crystal Structure of IgG1 b12: Implications for Vaccine Design and Antibody Neutralization


FRIDAY, MARCH 30

07:00—08:00
Breakfast

Torreys/Castle Peaks
08:00—11:00
Antiviral Immunity and Antigen Processing (Joint)
Meeting has ended...abstracts no longer viewable online.

Crestone/Red Cloud
* Rafi Ahmed, Emory University School of Medicine, USA
Vaccines and Immune Memory

Kenneth L. Rock, University of Massachusetts Medical School, USA
Immune Surveillance of Viral Infections

Francis V. Chisari, The Scripps Research Institute, USA
Noncytopathic Control of Viral Infections by the Immune Response

Giuseppe Pantaleo, Centre Hospitalier Universitaire Vaudois, Switzerland
Skewed Maturation of Memory HIV-Specific CD8 T Lymphocytes

09:20—09:40
Coffee Break

Shavano Foyer/Lobby
11:00—13:00
Poster Setup

Torreys/Shavano
16:00—18:00
POSTER SESSION 2: Antiviral Immunity and Antigen Processing/Novel Vaccine Approaches

Torreys/Shavano
17:00—18:00
Social Hour

Shavano Foyer/Lobby
20:00—21:00
Coffee Available

Shavano Foyer/Lobby
20:00—22:00
Novel Vaccine Approaches
Meeting has ended...abstracts no longer viewable online.

Shavano
* Mark B. Feinberg, IAVI International AIDS Vaccine Initiative, USA

Robert E. Johnston, Global Vaccines, Inc., USA
Alphavirus Vaccine Vectors

Philip R. Johnson, Children's Hospital of Philadelphia, USA
Novel SIV/HIV Vaccines Based on Recombinant Adeno-Associated Virus Vectors

Mark J. Newman, Geovax Inc, USA
The Multi-Epitope Approach to Development of HIV Vaccines


Following Session is for HIV Pathogenesis (J7)

20:00—22:00
Viral Life Cycle
Meeting has ended...abstracts no longer viewable online.

Crestone/Red Cloud
Mario Stevenson, University of Miami, Leonard M. Miller School of Medicine, USA
Role of Primate Lentiviral Nef Proteins in Altering Permissiveness of the Host to Viral Replication

Dan R. Littman, HHMI/New York University School of Medicine, USA
HIV-Receptor Interactions

* Warner Craig Greene, Gladstone Institute of Virology and Immunology, USA
Host-Virus Interactions and HIV Pathogenesis


SATURDAY, MARCH 31

07:00—08:00
Breakfast

Torreys/Castle Peaks
08:00—11:00
HIV Persistence - Challenges for Elimination (Joint)
Meeting has ended...abstracts no longer viewable online.

Crestone/Red Cloud
* Robert F. Siliciano, Johns Hopkins University School of Medicine, USA
Persistent Reservoirs of HIV

Mark Dybul, National Institutes of Health, USA

David D. Ho, Aaron Diamond AIDS Research Center, USA
The Persistence of the Latent Reservoir on Antiretroviral Therapy is Exacerbated by Incomplete Suppression of HIV-1 Replication

James I. Mullins, University of Washington, USA
Compartments and Reservoirs of HIV Infection in vivo

09:20—09:40
Coffee Break

Shavano Foyer/Lobby
11:00—13:00
Poster Setup

Torreys/Shavano
16:00—18:00
POSTER SESSION 3: HIV Persistence/Novel Vaccine Approaches -Animal Studies

Torreys/Shavano
17:00—18:00
Social Hour

Shavano Foyer/Lobby
20:00—21:00
Coffee Available

Shavano Foyer/Lobby
20:00—22:30
Novel Vaccine Approaches - Animal Studies
Meeting has ended...abstracts no longer viewable online.

Shavano
* Neal NMI Nathanson, University of Pennsylvania, USA

David I. Watkins, University of Miami, USA
SIV-Specific CTL in Primary Infection

Harriet L. Robinson, GeoVax Inc., USA
Multiprotein DNA/MVA Vaccine, Control of a Mucosal Challenge and Prevention of AIDS by a Memory T Cell Response

John W. Shiver, Sanofi Pasteur, USA
Comparative Studies of Several HIV Vaccine Approaches


Following Session is for HIV Pathogenesis (J7)

20:00—22:00
HIV Receptors, Tropism
Meeting has ended...abstracts no longer viewable online.

Crestone/Red Cloud
* Julie M. Overbaugh, Fred Hutchinson Cancer Research Center, USA
Evolution and Selection of T-Cell-Tropic Retroviruses that use Novel Receptors

Ronald P. van Rij, Radboud University Medical Center, Netherlands
HIV-1 Coreceptor Usage and Its Implications for T Cell Tropism in vivo

Edward A. Berger, NIAID, National Institutes of Health, USA
Receptor-Based Intervention Strategies

Leonid Margolis, NICHD, National Institutes of Health, USA
Short Talk: Why Different Coreceptor Usage Leads to Different Pathogenesis in Human Lymphoid Tissue


SUNDAY, APRIL 1

07:00—08:00
Breakfast

Torreys/Castle Peaks
08:00—11:00
New Investigators/Late Breakers
Meeting has ended...abstracts no longer viewable online.

Shavano
* Robert Paul Johnson, Harvard Medical School, New England Primate Research Center, USA

Meg Trahey, University of Montana, USA
Env-CD4-CCR5 Protein Complexes Elicit Antibodies that Neutralize Primary Isolates of HIV-1

David C. Montefiori, Duke University Medical Center, USA
Neutralizing Antibodies Associated with Viremia Control Following Treatment-Interruption in HIV-1-Infected Individuals

Surojit Sarkar, Pennsylvania State University, USA
Fine Specificity Analysis of Broadly Reactive and Type Specific CD4+ T Helper Responses in Macaques Vaccinated with Attenuated Simian Immunodeficiency Virus

Luzheng Liu, Brigham and Women's Hospital, USA
A Novel Flow Cytometric Cytotoxicity Assay to Evaluate CTL Responses Against HIV Antigens

Wendy Lisa Trigona, Merck Research Laboratories, USA
Use of Peptide Mixes for Detecting T Cell Responses to HIV by Cytokine Flow Cytometry

Claudio Vita, Commissariat Energie Atomique, France
Engineering CD4 Mimics, Inhibiting HIV-1 Entry and Exposing Envelope Neutralizing Epitopes

Larry A. Harshyne, Thomas Jefferson University, USA
Live-Cell Antigen Transfer Between Dendritic Cells: Implications for Expanding and Regulating Immune Responses

Shane Crotty, La Jolla Institute for Allergy and Immunology, USA
Protection of Macaques from a Virulent SIV(mac251) Vaginal Challenge Using Sabin Strain Live Poliovirus Vaccine Vectors (SabRV) Expressing a Defined Library of SIV Antigens

David B. Weiner, Wistar Institute, USA
Plasmid Vaccines Encoding Multiple HIV-1 Antigens Which Includes the Vpr Accessory Gene Markedly Reduce Vaccine Effectiveness and Antigen-Specific Effector T Cell Function in vivo Resulting in CD4 Cell Loss and Increased Viral Loads in Rhesus Macaqu

Jay A. Berzofsky, NCI, NIH, USA
Role of Mucosal Immunization and CTL in Resistance to Mucosal Viral Transmission in Mice and Rhesus Macaques

Jeffrey D. Lifson, Leidos Biomedical Research, Inc., USA
Transient Post-Inoculation Antiretroviral Drug Treatment Facilitates Development of SIV-Specific Cellular Immune Responses and Control of Viral Replication in SIV-Infected Rhesus Macaques


Following Session is for HIV Pathogenesis (J7)

08:00—11:00
CD4 Depletion/Renewal/Viral Load
Meeting has ended...abstracts no longer viewable online.

Crestone/Red Cloud
* Crystal L. Mackall, Stanford University, USA
Restoring Immune Competence Following T Cell Depletion: It Takes a Village

Daniel C. Douek, NIAID, National Institutes of Health, USA
Thymus Function in HIV Disease

Frank Miedema, Central Laboratories Blood Transfusion, Netherlands
HIV-1 Pathogenesis: Immune Hyperactivation and Failing Thymic Homeostasis

Laura A. Napolitano, Gladstone Institute of Virology and Immunology, USA
Maintenance of T Cell Homeostasis During the Course of HIV Disease Progression

09:20—09:40
Coffee Break

Shavano Foyer/Lobby
11:00—13:00
Poster Setup

Torreys/Shavano
14:00—16:00
VACCINE WORKSHOP 2: Practical Considerations in the Evaluation of Candidate AIDS Vaccines

Crestone
* Peggy Johnston, NIAID, National Institutes of Health, USA
Introduction

Wayne C. Koff, Human Vaccines Project, USA
Accelerating AIDS Vaccine Development

Rose A. McCullough, AIDS Vaccine Advocacy Coalition, USA
Community and Advocates Perspectives on AIDS Vaccine Trials

Salim S. Abdool Karim, University of KwaZulu-Natal, South Africa
Perspectives from the Developing World on AIDS Vaccine Trials

Kathleen M. MacQueen, Centers for Disease Control, USA
Evolving Ethical Issues and HIV Vaccine Trials


Following Session is for HIV Pathogenesis (J7)

14:00—16:00
WORKSHOP 2: Late Breakers

Red Cloud
Jason John Coull, University of Texas Southwestern Medical Center, USA
Localization of Histone Deacetylase 1 at the Promoter of Inactive Integrated Human Immunodeficiency Virus Type 1

Silvija I. Staprans, Emory University, USA
AIDS Pathogenesis Elucidated by Divergent Host Responses During SIV Infection of Natural and Non-Natural Hosts

Victor Appay, INSERM U1135 - CIMI, France
Difference in CD8+ T Cell Maturation According to Viral Specificity

Jaisri R. Lingappa, University of Washington, USA
Identification of a Nucleotide-Binding Host Factor Essential for Immature HIV Capsid Assembly

Roger J. Pomerantz, Seres Therapeutics, Inc., USA
Stratifying Residual HIV-1 Disease and Reservoirs: Virological and Immunological Delineation of Subgroups of HIV-1 Infected Individuals on Suppressive HAART

Gadi Borkow, R Ben-Ari Institute of Clinical Immunology, Israel

Melissa J. Churchill, Burnet Institute for Medical Research, Australia
Evolution of Promoter Activities of Attenuated Strains of HIV-1

Homira Behbahani, Karolinska Institutet, Sweden
Nef-Mediated Inhibition of Perforin Expression

David McDonald, National Institute of Allergy and Infectious Disease, USA
Imaging of Cytoplasmic HIV Reverse Transcription Complexes by Correlative Electron Microscopy

16:00—18:00
POSTER SESSION 4: Late Breaking Developments/Mucosal Transmission and Immunity/Clinical HIV Vaccine Trials/Immune Reconstitution

Torreys/Shavano
17:00—18:00
Social Hour

Shavano Foyer/Lobby
20:00—21:00
Coffee Available

Shavano Foyer/Lobby
20:00—22:00
Mucosal Transmission and Immunity
Meeting has ended...abstracts no longer viewable online.

Shavano
* Ashley T. Haase, University of Minnesota, USA

Marian R. Neutra, Children's Hospital Boston, USA
Transport of Antigens and Viruses to the Mucosal Immune System and Induction of Secretory Antibodies on Mucosal Surfaces

Christopher J. Miller, University of California, Davis, USA
Earliest Events in SIV Vaginal Transmission

Yvette van Kooyk, Vrije University Medical Center, Netherlands
DC and HIV Dessemination


Following Session is for HIV Pathogenesis (J7)

20:00—22:00
Viral Assembly and Release
Meeting has ended...abstracts no longer viewable online.

Crestone/Red Cloud
Jeremy Luban, University of Massachusetts Medical School, USA
Host Factors and HIV-1 Replication

James E.K. Hildreth, UC Davis College of Biological Sciences, USA
Adhesion Molecules, Lipid Rafts, and HIV Pathogenesis

* Eric O. Freed, NCI, National Institutes of Health, USA
Viral and Host Determinants of HIV-1 Assembly and Release


MONDAY, APRIL 2

07:00—08:00
Breakfast

Torreys/Castle Peaks
08:00—11:00
Clinical HIV Vaccine Trials
Meeting has ended...abstracts no longer viewable online.

Shavano
* Emilio A. Emini, Bill and Melinda Gates Foundation, USA
Pre-Clinical Evaluation of Merck's HIV Vaccine Candidates Currently in Clinical Trials

Phillip W. Berman, University of California, Santa Cruz, USA
Development and Clinical Testing of Multivalent gp120 Vaccines

M. Juliana McElrath, Fred Hutchinson Cancer Research Center, USA
Cellular Immune Responses Induced by Candidate HIV-1 Vaccines


Following Session is for HIV Pathogenesis (J7)

08:00—11:00
Anti-HIV Treatment - Directions and Problems
Meeting has ended...abstracts no longer viewable online.

Crestone/Red Cloud
* Brenda Lein, Project Inform, USA
AIDS Therapies: Problems, Potential and Possibilities

Alfredo Garzino-Demo†, University of Maryland School of Medicine, USA
New Biologic Approaches to Control HIV-1

Morris Schambelan, University of California, San Francisco, USA
Metabolic Consequences of HIV Treatment

Douglas D. Richman, University of California, San Diego, USA
Viral Evolution During Treatment

09:20—09:40
Coffee Break

Shavano Foyer/Lobby
16:00—17:00
Coffee Available

Shavano Foyer/Lobby
16:00—18:00
Immune Reconstitution - Problems and Prospects (Joint)
Meeting has ended...abstracts no longer viewable online.

Crestone/Red Cloud
* Brigitte Autran, Hôpital Pitié-Salpétrière, UPMC, France
Immune Reconstitution and Antiviral Therapy

Douglas F. Nixon, George Washington University, USA
Immune Control of HIV Following Antiviral Therapy

Nina Bhardwaj, Icahn School of Medicine at Mt Sinai, USA
Modulation of Immunity by Dendritic Cells

19:00—20:00
Social Hour

Long's Foyer
20:00—22:00
Banquet

Gray's/Long's
21:00—00:00
Entertainment

Gray's/Long's

TUESDAY, APRIL 3

 
Departure


*Session Chair †Invited, not yet responded.



We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676